Press news Biocartis Group NV: Invitation to the Extraordinary Shareholders’ Meeting
04 Settembre 2020 - 7:00AM
Press news Biocartis Group NV: Invitation to the Extraordinary
Shareholders’ Meeting
PRESS RELEASE: REGULATED INFORMATION4 September 2020, 07:00
CEST
Invitation to the Extraordinary
Shareholders’ Meeting
Mechelen, Belgium, 4 September
2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’),
an innovative molecular diagnostics company (Euronext Brussels:
BCART), has the honor to invite its shareholders, holders of
subscription rights, holders of convertible bonds, directors and
statutory auditor to a new extraordinary shareholders' meeting that
will be held on Friday 25 September 2020 at 9:00 a.m. CEST, at
the offices of the Company at Generaal de Wittelaan 11B, 2800
Mechelen, Belgium. The legally required quorum to validly
deliberate and vote on the agenda items of the extraordinary
shareholders' meeting held on 2 September 2020 was not reached.
In light of the COVID-19 pandemic, it is
currently envisaged that the measures imposed by the Belgian
government to deal with this pandemic, such as the obligation to
guarantee a distance of 1.5 meters between each person, may still
be in effect as of 25 September 2020, date of the Company's
extraordinary shareholders' meeting. These measures are in the
interest of the health of individual securities holders, as well as
of the employees of the Company and others who are responsible for
organizing the shareholders' meeting. It can also not be excluded
that the Belgian government will again impose additional measures.
We will monitor the situation closely and will disclose all
relevant information and measures that have an impact on the
shareholders' meeting on the Biocartis website.
In view hereof, the Company recommends that the
shareholders that wish to participate in the extraordinary
shareholders' meeting make use, as much as practically possible, of
the right to vote through voting by mail or by proxy to the
chairman of the Board of Directors. Furthermore, it is recommended
that holders of securities that wish to exercise their right to ask
questions regarding the items on the agenda of the extraordinary
shareholders' meeting do so in writing. The modalities of the
aforementioned means of participation in the extraordinary
shareholders' meeting are set out in the convening notice and in
the relevant forms for voting by mail or by proxy.
In order to be admitted to the extraordinary
shareholders’ meeting, the holders of securities issued by the
Company must comply with Article 7:134 of the Belgian Code of
Companies and Associations and the articles of association of the
Company, and fulfill the formalities described in the convening
notice. The convening notice and other documents relating to the
shareholders’ meetings can be consulted on the Company’s
website.
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail
rdegrave@biocartis.comtel
+32 15 631 729 mobile +32 471 53 60
64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer. More
information: www.biocartis.com. Follow us on Twitter:
@Biocartis_.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
This press release is not for distribution, directly or indirectly,
in any jurisdiction where to do so would be unlawful. Any persons
reading this press release should inform themselves of and observe
any such restrictions. Biocartis takes no responsibility for any
violation of any such restrictions by any person. Please refer to
the product labeling for applicable intended uses for each
individual Biocartis product. This press release does not
constitute an offer or invitation for the sale or purchase of
securities in any jurisdiction. No securities of Biocartis may be
offered or sold in the United States of America absent registration
with the United States Securities and Exchange Commission or an
exemption from registration under the U.S. Securities Act of 1933,
as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Grafico Azioni Biocartis Group NV (EU:BCART)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Biocartis Group NV (EU:BCART)
Storico
Da Apr 2023 a Apr 2024